BioSpace News Archive

Leading sports nutrition brand Novex Biotech alongside Authentic Brands Group (ABG), a global brand owner, marketing and entertainment company, today announced World Golf Hall of Fame member, Greg Norman, as its new Brand Ambassador representing Novex’s full product assortment

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020, before the U.S. financial markets open

Elpis Biopharmaceuticals today announced the closing of a $30 million Series A financing to propel solid tumor and hematological disease therapeutics through pre-clinical studies, which brings the company to a total of $40 million raised including seed funding.

– Third-Quarter Revenue of $743.3 Million – – Third-Quarter GAAP Earnings per Share of $2.03 and Non-GAAP Earnings per Share of $2.33 – – Increases 2020 Guidance –

Company Will Report Data from Phase 2a Sensorineural Hearing Loss (SNHL) Study in Late Q1 2021 First Patient Dosed in Phase 1b Study of Age-Related Hearing Loss; Additional Phase 1b Study for Severe SNHL Patients to Start This Quarter

Agency-wide CRADA agreement also includes studies with Brain-Chip in Alzheimer’s disease, Intestine-Chip in microbiome health, and Liver-Chip in individualized toxicity responses

First patient dosed at the Emory University School of Medicine in Atlanta, Georgia Trial will evaluate lenzilumab with remdesivir, compared to placebo and remdesivir, in up to 200 patients hospitalized with COVID-19 ’

Castle Biosciences to Present Data at the American Society of Dermatopathology (ASDP) 57 th Virtual Annual Meeting Presentations to highlight two of Castle’s skin cancer gene expression profile tests

Under Amulet’s ownership, Synteract drove organic growth, integrated several strategic acquisitions, more than doubled EBITDA and expanded its global delivery footprint

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported second quarter fiscal 2021 revenue of $209.8 million, a sequential increase of 27% compared to Q1 fiscal year 2021 and a year over year increase of 2% compared to Q2 fiscal year 2020 despite the negative impact of COVID-19. Operating income was $61.3 million up 2%, compared to $60.2 million in the same period of fisc